Telix Pharmaceuticals (STU:T3X) Long-Term Debt : €11.3 Mil (As of Jun. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Telix Pharmaceuticals Long-Term Debt?

Telix Pharmaceuticals's Long-Term Debt for the quarter that ended in Jun. 2024 was €11.3 Mil.

Telix Pharmaceuticals's quarterly Long-Term Debt declined from Jun. 2023 (€7.6 Mil) to Dec. 2023 (€5.0 Mil) but then increased from Dec. 2023 (€5.0 Mil) to Jun. 2024 (€11.3 Mil).

Telix Pharmaceuticals's annual Long-Term Debt increased from Dec. 2021 (€0.0 Mil) to Dec. 2022 (€2.1 Mil) and increased from Dec. 2022 (€2.1 Mil) to Dec. 2023 (€5.0 Mil).

Telix Pharmaceuticals Long-Term Debt Historical Data

The historical data trend for Telix Pharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telix Pharmaceuticals Long-Term Debt Chart

Telix Pharmaceuticals Annual Data

Trend

Sep99

Sep00

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

0.18

0.06

2.11

5.04

Telix Pharmaceuticals Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Long-Term Debt	Get a 7-Day Free Trial									1.34	2.11	7.59	5.04	11.33

Telix Pharmaceuticals (STU:T3X) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Telix Pharmaceuticals Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Telix Pharmaceuticals's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Telix Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telix Pharmaceuticals Ltd (STU:T3X) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

TLX:USA TLPPF:USA TLX:Australia

Address

55 Flemington Road, Suite 401, North Melbourne, Melbourne, VIC, AUS, 3051

Website

https://www.telixpharma.com

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.

Telix Pharmaceuticals Headlines

No Headlines